Results 181 to 190 of about 6,749,585 (382)
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva+5 more
wiley +1 more source
Evidence-based medicine and the practicing clinician
Finlay A. McAlister+3 more
openalex +2 more sources
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon+13 more
wiley +1 more source
Evidence-based design: theoretical and practical reflections of an emerging approach in office architecture [PDF]
Evidence-based design is a practice that has emerged only relatively recently, inspired by a growing popularity of evidence-based approaches in other professions such as medicine.
Budgen, A.+4 more
core
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková+14 more
wiley +1 more source
Many questions cannot be answered by evidence based medicine [PDF]
O. Dearlove+3 more
openalex +1 more source
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim+11 more
wiley +1 more source